Menlo Care Landmark midline catheter adverse events will be evaluated in upcoming study.
This article was originally published in The Gray Sheet
MENLO CARE LANDMARK MIDLINE CATHETER: COMPARATIVE ADVERSE EVENTS STUDY will be conducted in 1996, the company says in a Jan. 12 "device bulletin" sent to 1,500 physicians. The goal of the study is to ascertain the cause of a number of adverse events reported to the company for the Landmark catheters. Menlo Care notes that testing to date "has not indicated any sensitivity or allergy to the device material," but the firm is working with FDA to "to try to understand the nature of the events and how to prevent them."
You may also be interested in...
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.